)
)
Phagenyx
Phagenesis Ltd. is a neurostimulation company focused on restoring swallowing function in patients with neurogenic dysphagia. The company developed Phagenyx®, the pharyngeal electrical stimulation (PES) system designed to promote recovery of safe swallowing by stimulating the pharyngeal neural pathways. Clinical studies and real-world evidence have demonstrated meaningful improvements in swallowing safety, aspiration risk, nasogastric tube removal, and earlier tracheostomy decannulation, particularly in severe and tracheotomized patients.
Phagenesis works closely with researchers and clinical leaders to integrate evidence-based neurostimulation into routine care pathways. With more than 30 scientific publications and growing support from international stroke and dysphagia guidelines, the company is helping shift dysphagia management from compensatory care toward active neurorehabilitation.
By combining clinical evidence, practical bedside workflow integration, and a strong focus on patient recovery, Phagenesis aims to reduce complications such as aspiration pneumonia, accelerate oral feeding, and improve care efficiency across acute and rehabilitation settings.
What will be showcased on our stand?
Phagenyx® therapy is designed to restore safer swallowing in adults with neurogenic oropharyngeal dysphagia after stroke, prolonged mechanical ventilation, traumatic brain injury, or other neurological injury. Delivered bedside through a treatment catheter with integrated electrodes positioned in the pharynx, the system provides targeted pharyngeal electrical stimulation. By activating afferent sensory pathways, Phagenyx supports neuroplastic reorganization of the swallowing network, addressing the neurological cause of dysphagia rather than only compensating for symptoms.
Clinical studies have shown meaningful improvements in swallowing safety, reduced aspiration risk, earlier nasogastric tube removal, and faster tracheostomy decannulation, particularly in severe post-stroke and post-extubation patients. Designed for stroke units, ICUs, and neurorehabilitation settings, Phagenyx integrates into established dysphagia pathways and helps shift care toward active neurorehabilitation and recovery. The therapy is supported by 30+ peer-reviewed publications and is recommended in international and national guidelines.